secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001326732-24-000034
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination
--------------------------------------------------------------------------------

- Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.
- Plamotamab is Phase 2 ready, having completed Phase 1 enrollment in hematologic cancers in late 2023.
- Janssen retains rights to develop B-cell targeting CD28 bispecifics, including JNJ-9401 and JNJ-1493, now in Phase 1.
- Two collaboration agreements with Janssen continue; Xencor remains eligible for milestones and royalties on retained CD28 programs.
- Xencor has opt-in rights to co-fund development of JNJ-9401 (20%) and JNJ-1493 (15%) upon proof-of-concept.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000034/0001326732-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000034/xncr-20240613.htm
  HTML page:      https://secwatch.observer/filing/0001326732-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer